Abstract
Several chemically unrelated agents has been developed and introduced in the past decade, to supplement the earlier antidepressants. These include inhibitors of the reuptake of serotonin [the selective serotonin reuptake inhibitors (SSRI)] or noradrenaline (reboxetine) or both (milnacipran and venlafaxine), as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine. Like the earlier drugs, these newer antidepressants are almost totally biotransformed before excretion, except for milnacipran whose clearance appears to be due equally to both urinary excretion and metabolism. Sometimes — as in the case of moclobemide — up to 20 metabolites have been identified in body fluids. In some cases, however, only a few metabolites have been detected, and a substantial proportion of the dose remains unaccounted for (e.g. fluoxetine and fluvoxamine).
Metabolism generally proceeds through sequential or parallel oxidative pathways. These may be affected to varying degrees by physiological and pathological factors and those mediated by cytochrome P450 (CYP) 2D6 and CYP2C19 through genetic polymorphism. Some are influenced by chirality (e.g. the dealkylation of citalopram and fluoxetine), although information on this aspect of disposition is still lacking for other drugs existing as racemates (e.g. mirtazepine and tianeptine) and milancipran, which is probably a mixture of 4 stereoisomers. Others again are saturable within the therapeutic range of doses (e.g. some pathways of metabolism of fluoxetine, fluvoxamine, nefazodone, paroxetine and venlafaxine). This may explain the individual variability with all these drugs which, from the pharmacokinetic point of view, is the same as with tricyclic agents.
Our knowledge of the isoenzymes involved in the various oxidation pathways and their relevance for potential drug interactions varies from a considerable amount for most of the SSRI and nefazodone, to minimal for reboxetine and tianeptine. This information is useful for predicting the pharmacokinetic interactions mediated through inhibition of specific isoenzymes. This would be better appreciated if the enzymatic mechanisms involved in the biotransformation of the metabolite(s), and their role in drug interactions, were also known. This information is still lacking for some drugs, although metabolites may exhibit in vitro inhibitory potencies of similar to (paroxetine and its M2 metabolite as inhibitors of CYP2D6) or even greater than that of the parent drug (norfluoxetine is more potent than fluoxetine as an inhibitor of CYP3A3/4, and in view of the longer half-life (t1/2) of the metabolite the potential for interactions may persist for weeks after discontinuation of the parent drug).
While we do know something about the biological activity of the metabolites of some of these drugs, we know very little about others. With few exceptions this knowledge refers only to the major metabolite(s) and regards the main in vitro effects as exerted by the parent drug. However, in vitro potency and selectivity may not translate directly into in vivo, and either major or minor metabolites may have characteristic in vitro and in vivo properties. For example, unlike the parent drug some minor ring-opened metabolites of moclobemide have monoamine oxidase-B inhibitory activity in the rat, and the nefazodone metabolite m-chlorophenyl-piperazine shows activity on 5-HT2C receptors in rats and humans.
Data on the brain-to-blood partition of metabolites compared with their parent drug are available only in a few cases. They are still not known for the main metabolites of fluvoxamine, milnacipran, mirtazapine, moclobemide, nefazodone, paroxetine, reboxetine and venlafaxine, despite the fact that total blood concentrations do not always reflect the metabolite: parent drug ratio in brain. Thus, in most cases, we do not really know what part hepatic metabolism plays in the overall effect of the administered parent drug.
Similar content being viewed by others
References
Coccaro EF, Siever LJ. Second generation antidepressants: a comparative review. J Clin Pharmacol. 1985; 25: 241–60.
Blackwell B, Simon JS. Second-generation antidepressants. Drugs Today. 1986; 22: 611–33.
Hollister LE. Current antidepressants. Annu Rev Pharmacol Toxicol. 1993; 26: 23–37.
Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs. 1989; 37: 713–38.
Möller H-J, Volz H-P. Drug treatment of depression in the 1990s: an overview of achievements and future possibilities. Drugs. 1996; 52: 625–6.
Skerritt U, Evans R, Montgomery SA. Selective serotonin reuptake inhibits in older patients: a tolerability perspective. Drugs Aging. 1997; 10: 209–18.
Amsterdam J, Brunswick D, Mendels J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry. 1980; 137: 653–62.
Guthrie S, Lane EA, Linnoila M. Monitoring of plasma drug concentrations in clinical psychopharmacology. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1323–9.
Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem. 1988; 34: 822–8.
Orsulak PJ. Therapeutic monitoring of antidepressant drugs: guidelines updated. Ther Drug Monit. 1989; 11: 497–507.
Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin Pharmacokinet. 1990; 18: 434–59.
Potter WZ, Manji HK. Antidepressants, metabolites, and apparent drug resistance. Clin Neuropharmacol. 1990; 13 Suppl. 1: S45–53.
Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet. 1995; 28: 26–40.
Caccia S, Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol Res. 1992; 26: 317–29.
Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 Suppl.: 14–34.
DeVane CL. Pharmacokinetics of the newer antidepressants: Clinical relevance. Am J Med. 1994; 97 Suppl. 6A: 13S–23S.
Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet. 1994; 27: 307–30.
Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996; 31: 444–69.
Rudorfer MV, Potter WZ. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs. 1997; 7: 273–312.
Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol. 1983; 15: 349S–55S.
Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991; 41: 225–53.
Milne CJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991; 41: 450–77.
Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32: 481–508.
Wong DT, Bymaster FP, Reid LR, et al. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology. 1993; 8: 337–44.
Fuller, RW, Wong DT. Serotonin re-uptake blockers in vitro and in vivo. J Clin Psychopharmacol. 1987; 7: 365–435.
Murdoch D, McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992; 44: 604–24.
Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997; 32: Suppl. 1: 22–30.
Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32: 313–34.
Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994; 30: 251–9.
Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1996; 11 Suppl. 5: 31–61.
Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996; 153: 311–20.
Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther. 1997; 61: 619–27.
Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther. 1995; 58: 399–403.
Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992; 34: 262–5.
Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992; 34: 256–61.
von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995; 15: 125–31.
Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther. 1997; 62: 279–86.
Hartter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology. 1993; 110: 302–8.
Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989; 80 Suppl. 350: 60–75.
Crewe S, Lennard MS, Tucker GT, et al. The effect of paroxetine and other specific serotonin re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol. 1991; 32: 658P–9P.
Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992; 33: 521–3.
Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51: 278–87.
Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993; 44: 349–55.
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997; 32 Suppl. 1: 1–21.
Ozdemir V, Naranjo CA, Herrmann N, et al. paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytocrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997; 62: 334–47.
Tremaine LM, Welch WM, Ronfeld RA. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos. 1989; 17: 542–50.
Sindrup SH, Brøsen K, Hansen MGJ, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993; 15: 11–7.
Baumann P, Nil R, Souche A, et al. A double-blind placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996; 16: 307–14.
Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997; 280: 927–33.
Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit. 1995; 17: 273–9.
Foglia JP, Pollock BG, Kirshner MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull. 1997; 33: 109–12.
Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 1997; 7: 1–10.
Bondolfi G, Chautems C, Rochat B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology. 1996; 128: 421–5.
Torok-Both GA, Baker GB, Coutts RT, et al. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr B. 1992; 579: 99–106.
Fjordside L, Jeppesen U, Eap CB et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine [abstract]. Eur J Clin Pharmacol 1997; Suppl. I: A127.
Fuller RW, Snoddy HD, Perry KW. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine. Biochem Pharmacol. 1978; 27: 193–8.
Anelli M, Bizzi A, Caccia S, et al. Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs. J Pharm Pharmacol. 1992; 44: 696–8.
Caccia S, Fracasso C, Garattini S, et al. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology. 1992; 31: 343–7.
Caccia S, Anelli M, Codegoni AM, et al. The effect of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. Br J Pharmacol. 1993; 110: 355–9.
Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994; 26: 201–14.
Hamelin BA, Turgeon J, Vallée F et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996; 60: 512–21.
Otton SV, WU D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P4562D6 activity. Clin Pharmacol Ther. 1993; 53: 401–9.
Harvey A, Preskorn S. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996; 16: 345–55.
Brosen K. Are pharmacokinetic drug interactions with the SSRIS and issue? Int Clin psychopharmacol 1996; 11 Suppl. 1: 23–7.
Meyer UA, Amrein R, Balant LP et al. Antidepressants and drug-metabolizing enzymes: expert group report. Acta Psychiatr Scand. 1996; 93: 71–9.
Bertilsson L, Dahl M-L, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl. 1997; 391: 14–21.
Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. Clin Pharmacokinet. 1997; 33: 454–71.
Zussman BD, Davie CC, Fowles SE, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol. 1995; 39: 550.
Alderman J, Preskorn SH, Greenblatt DJ, et al. desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997; 17: 284–91.
Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997; 62: 145–56.
Carson SW. Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders. Psychopharmacol Bull. 1996; 32: 555–68.
Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P4503A-mediated drug metabolism in vivo. Psychopharmacol Bull. 1997; 33: 659.
Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology. 1996; 14: 225–31.
Fuller RW, Hemrick-Luecke SK, Littlefield ES, et al. Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Prog Neuropsychopharmacol. 1995; 19: 135–49.
Garattini S, Bizzi A, Caccia S, et al. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline, Int J Obes Relat Metab Disord 1992; 16 Suppl. 3: S43–50.
Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996; 11 Suppl. 4: 15–27.
Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996; 11 Suppl. 4: 10–4.
Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 1986; 35: 4493–7.
Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs): pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs. 1995; 4: 79–89.
Bonnaud B, Cousse H, Mouzin G, et al. 1-Aryl-2-(aminoethyl) cyclopropanecarboxylic acid derivatives: a new series of potential antidepressants. J Med Chem. 1987; 30: 318–25.
Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother. 1995; 29: 387–95.
Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther. 1994; 56: 14–21.
Wang CP, Howell SR, Scatina J, et al. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality. 1992; 4: 84–90.
Howell SR, Husbands GEM, Scatina JA, et al. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica. 1993; 23: 349–59.
Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991; 23: 191–9.
Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996; 41: 149–56.
von Moltke LL, Greenblatt DJ, Duan SX, et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology. 1996; 128: 398–407.
Otton SV, Ball SE, Cheung SW, et al. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors. Clin Pharmacol Ther. 1994; 55: 141.
Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism. Comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYPIA2. Br J Clin Pharmacol. 1997; 43: 619–26.
Troy SM, Lucki I, Peirgies AA, et al. Pharmacokinetic and phar macodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol. 1995; 35: 410–9.
Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995; 15: 387–98.
Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol. 1996; 16 Suppl. 2: 37S–50S.
Melloni P, Delia Torre A, Lazzari E, et al. Configuration studies on 2[α-ethoxyphenoxy][benzyl]morpholine FCE 20124. Tetrahedron. 1985; 41: 1393–9.
Melloni P, Carniel G, Delia Torre A, et al. Potential antidepressant agents, α-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem Chim Ther. 1984; 19: 235–42.
Strolin Benedetti M, Frigerio E, Tocchetti P, et al. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality. 1995; 7: 285–9.
Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 1992; 149: 1592–4.
Bergami A, Fracasso C, Garattini S, et al. Brain uptake and acute indole-depleting effect of dexfenfluramine in squirrel monkeys after a high-dose regimen. Pharm Sci. 1995; 1: 45–8.
Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997; 7 Suppl. 1: S23–35.
Cocchiara G, Battaglia R, Pevarello P, et al. Comparison of the disposition and of the metabolic patterns of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet. 1991; 16: 231–9.
Pellizzoni C, Poggesi I, Jorgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos. 1996; 17: 623–33.
Edwards DMF, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995; 16: 443–60.
Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997; 53: 608–36.
Mayol RF, Cole CA, Luke GM, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos. 1994; 22: 304–11.
Caccia S, Fong MH, Garattini S, et al. Plasma concentrations of trazodone and 1-(3-chlorophenyl)-piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol. 1982; 34: 605–6.
Caccia S, Garattini S. 1-Arylpiperazine as active metabolites of (4-substituted aryl-1-piperazinyl)alkyl heterocyclic drugs. Acta Pharm Jugosl. 1990; 40: 441–60.
Caccia S, Vigano GL, Mingardi G, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988; 14: 171–7.
Bianchi G, Caccia S, Delia Vedova F, et al. The alpha2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur J Pharmacol. 1988; 151: 365.
Schmider J, Greenblatt DJ, von Moltkr LL, et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol. 1996; 41: 339–43.
Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997; 33: 260–75.
Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol. 1996; 42: 573–81.
Marino MR, Langenbacher KM, Uderman HD. Interaction of nefazodone (N) and fluoxetine (F). Clin Pharmacol Ther. 1996; 59: 180.
Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism of thioridazine in humans. Ther Drug Monit. 1995; 17: 333–5.
Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989; 25: 569–75.
Murphy DL, Lesch KP, Aulakh CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev. 1991; 43: 527–50.
Benjamin J, Greenberg BD, Murphy DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology. 1996; 127: 140–9.
Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996; 16: 19–25.
Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol. 1995; 49: 221–8.
Barbhaiya RH, Brady ME, Shukla UA, et al. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur J Clin Pharmacol. 1995; 49: 229–35.
Barbhaiya RH, Shukla UA, Natarajan CS, et al. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther. 1995; 58: 390–8.
Mocaër E, Rettori MC, Kamoun A. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin Neuropharmacol. 1988; 11 Suppl. 2: S32–42.
Mennini T, Garattini S. Neurobiology of tianeptine: a new pharmaceutic agent. Presse Med. 1991; 20: 1823–7.
Ansseau M. The paradox of tianeptine. Eur Psychiatry. 1993; 8 Suppl. 2: 89S–93S.
Wilde MI, Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 1995; 49: 411–39.
Grislain L, Gele P, Bertrand M, et al. The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. Drug Metab Dispos. 1990; 18: 804–8.
Oluyomi AO, Datla KP, Curzon G. Effects of the (+) and (−)-enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour. Neuropharmacology. 1997; 36: 383–7.
Larrey D, Tinel M, Letteron P, et al. Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450. Biochem Pharmacol. 1990; 40: 545–50.
Couet W, Girault J, Latrille F, et al. Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat. Eur J Drug Metab Pharmacokinet. 1990; 15: 69–74.
Carlhant D, Le Garrec J, Guedes Y, et al. Pharmacokinetics and bioavailability of tianeptine in the elderly. Drug Invest. 1990; 2: 167–72.
Demotes-Mainard F, Galley P, Manciet G, et al. Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly. J Clin Pharmacol. 1991; 31: 174–8.
Salvadori C, Merdjan H, Brouard R, et al. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis. Fundam Clin Pharmacol. 1990; 4: 663–71.
Royer RJ, Royer-Morrot MJ, Paille F, et al. Tianeptine and its main metabolite. Pharmacokinetics in chronic alcoholism and cirrhosis. Clin Pharmacokinet. 1989; 16: 186–91.
Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs. 1995; 4 Suppl. 1: 39–48.
Nutt D. Mirtazepine: pharmacology in relation to adverse effects. Acta Psychiatr Scand. 1997; 96 Suppl. 391: 31–7.
de Boer Th, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology. 1988; 27: 399–408.
Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 389–402.
Sandker GW, Vos RME, Delbressine LPC, et al. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica. 1994; 24: 143–55.
Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazepine in humans. Clin Drug Invest. 1997; 13: 37–46.
Poirier MF, Olié JP, Loo H, et al. Activité antidépressive, caractéristiques pharmacocinétiques et proprétés biochimiques de la cimoxatone, un nouvel IMAO-A réversible. Encéphale. 1983; IX: 331–43.
Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs. 1992; 43: 561–96.
Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs. 1996; 52: 450–74.
Volz HP, Gleiter CH, Struck M, et al. Brofaromine: insight into the nature of drug development. CNS Drugs. 1995; 3: 1–8.
Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet. 1995; 29: 292–32.
Schoerlin MP, Mayersohn M, Korn A, et al. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther. 1987; 42: 395–404.
Schoerlin MP, Horber FF, Frey FJ, et al. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol. 1990; 30: 272–84.
Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990; Suppl. 360: 94–97.
Jauch R, Griesser E, Oesterhelt G, et al. Biotransformation of moclobemide in humans. Acta Psychiatr Scand 1990; Suppl. 360: 87–90.
Schoerlin MP, Da Prada M. Species-specific biotransformation of moclobemide: a comparative study in rats and humans. Acta Psychiatr Scand 1990; Suppl. 360: 108–10.
Da Prada M, Kettler R, Keller HH, et al. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 1989; 248: 400–8.
Fritze J, Laux G, Sofic E, et al. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacology. 1989; 99: 252–6.
Guentert TW, Gram LF, Grange S, et al. Reversible interaction of moclobemide with CYP2D6 and CYP2C9. Clin Pharmacol Ther. 1994; 55: PI–57.
Gram LF, Brøsen K, and the Danish University Antidepressant Group. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol. 1993; 35: 649–52.
Spigset O, Granberg K, Hägg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998; 45: 257–63.
Sperker B, Backman JT, Kroemer HK. The role of β-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet. 1997; 33: 18–31.
Campbell B, Dard-Brunelle B, Caccia S. The use of pharmacokinetics in the assessment of dexfenfluramine safety. In: Nicolaidis S, editor. Obesity management and Redux™. San Diego: Academic Press, 1997: 65–80.
Matzke GR, St Peter WL. Clinical pharmacokinetics 1990. Clin Pharmacokinet. 1990; 18: 1–19.
Bartels, Albert K. Detection of Psychoative drugs using 19FMR spectroscopy. J Neural Transm Gen Sect. 1995; 99: 1–6.
Kennedy SH, Javanmard M, Vaccarino FJ. A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Can J Psychiatry. 1997; 42: 467–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caccia, S. Metabolism of the Newer Antidepressants. Clin Pharmacokinet 34, 281–302 (1998). https://doi.org/10.2165/00003088-199834040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199834040-00002